FDA drug classification: what it is (and isn’t) — the right U.S. frameworks and where to verify them

Overview

The phrase "FDA drug classification" does not point to a single system. Depending on context, it may refer to DEA controlled substance schedules, FDA recall classes, FDA-established pharmacologic class (EPC) in labeling, pregnancy and lactation labeling under PLLR, OTC monograph/GRASE status, Orange Book therapeutic equivalence codes, or the drug/device/combination-product determination. Each system has distinct legal authority, a dedicated public database, and its own operational consequences. As one peer-reviewed analysis notes, the FDA classification system was designed to guide new drug products through the application process and should be used only with caution for other purposes.

For regulatory professionals and pharmacy teams, the practical task is identifying which framework governs the specific decision at hand — substitution, clinical counseling, storage, recall response, or regulatory research. A single product can carry non-redundant designations across several of these systems simultaneously. The sections below define each system, clarify what it does and does not govern, and provide stepwise verification paths to the authoritative public sources.

What "FDA drug classification" can mean — the major U.S. systems at a glance

The United States does not operate a single unified drug classification registry. Multiple agencies and regulatory frameworks assign classifications for distinct statutory purposes, and their labels are not interchangeable. A branded oral analgesic, for instance, may simultaneously carry a DEA Schedule II designation, a Class I recall history, an EPC entry in its label, PLLR narrative subsections, and an Orange Book TE code — none of which is redundant with the others.

The six major systems a regulatory or compliance reader will encounter are:

• DEA controlled substance schedules (Schedules I–V): Govern abuse potential, prescribing controls, storage, and dispensing requirements under the Controlled Substances Act. FDA/HHS provides scientific recommendations; DEA holds scheduling authority and publishes decisions in the Federal Register. See DEA Drug Scheduling.
• FDA recall classifications (Class I–III): Signal the health-risk severity of a product removed or corrected; assigned by FDA and listed in FDA's recalls database.
• FDA-established pharmacologic class (EPC) and therapeutic categories: Label-level designations in Structured Product Labeling (SPL) that encode mechanism of action, physiologic effect, and chemical structure; searchable on DailyMed and summarized on FDA's General Drug Categories page.
• Pregnancy and lactation labeling (PLLR): Narrative subsections on approved labeling that replaced the legacy A–X letter categories for prescription drugs and biologics; viewable on DailyMed.
• OTC monograph / GRASE pathway: Administrative-order system for OTC active ingredients determined to be generally recognized as safe and effective; maintained in FDA's OTC Monographs database.
• Orange Book therapeutic equivalence (TE) codes: Indicate whether a generic drug product is therapeutically equivalent to a reference listed drug and hence generally substitutable; published in the Orange Book.

Understanding which system applies is the first step. The sections that follow define each system precisely and show where to verify status.

Controlled substance schedules (DEA; FDA/HHS provides scientific recommendations)

Controlled substance scheduling determines legal handling, prescribing, storage, and enforcement requirements for substances under the Controlled Substances Act. The DEA classifies substances into Schedules I–V based on accepted medical use and abuse or dependence potential; FDA/HHS provides the scientific and medical evaluation, but DEA makes the final determination and publishes it in the Federal Register.

For compliance tasks — ordering, storage, prescribing, and recordkeeping — always rely on the current DEA schedule rather than FDA label language. DEA rulemaking can alter a schedule between NDA review cycles, so monitoring the Federal Register for proposed and final scheduling rules is part of sound controlled-substance portfolio management.

FDA drug recall classifications (Class I–III)

FDA recall classifications assess the health-risk severity of products being removed or corrected. They are documented in FDA's Recalls, Market Withdrawals, & Safety Alerts database. Class I indicates a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II indicates possible temporary or medically reversible adverse health consequences. Class III indicates the product is not likely to cause adverse health consequences.

Recall classes relate strictly to market actions and consumer safety. They carry no information about abuse potential, scheduling, or substitutability. For recall status, consult FDA's recalls database directly, and confirm whether a recall is active or terminated before acting on it.

Therapeutic and pharmacologic classes (including FDA-established pharmacologic class, EPC)

The FDA-established pharmacologic class (EPC) is a label-level classification that aids regulatory review, labeling consistency, and SPL indexing. It encodes up to four attributes: mechanism of action (MoA), physiologic effect (PE), chemical structure (CS), and a broader pharmacologic class. These appear in the Highlights of Prescribing Information and in the SPL XML, and are searchable on DailyMed.

Broader plain-language therapeutic categories — analgesics, antibacterials, antiarrhythmics, and others — are summarized on FDA's General Drug Categories page. Use EPC information for labeling work, regulatory submissions, and formulary reporting; apply it with caution for comparative effectiveness analysis or cross-system taxonomy mapping, because it was designed specifically to support new-drug review and SPL indexing, not as a universal analytic taxonomy.

Pregnancy and lactation labeling (PLLR replaced A–X)

PLLR provides narrative risk subsections on pregnancy, lactation, and reproductive potential in Section 8 of approved labeling, replacing the legacy A–X letter categories for prescription drugs and biologics. The PLLR format supplies risk summaries, clinical data, and counseling considerations rather than a single-letter summary. Current PLLR-compliant labeling is viewable on DailyMed.

Legacy A–X letters may still appear on older labels not yet updated, but they should not be used as the basis for counseling or policy language where PLLR-compliant labeling exists. When in doubt, check the label date on DailyMed and prefer the most recent active version.

OTC Monograph and GRASE vs NDA/BLA

The OTC Monograph and GRASE pathway defines conditions under which OTC active ingredients are generally recognized as safe and effective. The CARES Act modernized monograph administration into an administrative-order process: products conforming to a final monograph order may be marketed without individual product approval. Consult FDA's OTC Monographs database for current orders.

If no applicable monograph exists, or the product does not conform to the conditions of a final order, the sponsor must pursue an NDA or BLA. The distinction matters operationally: a GRASE determination does not constitute an approved application and does not generate an Orange Book listing in the same way.

Orange Book therapeutic equivalence (TE) codes

Orange Book TE codes indicate FDA's determination of whether a specific generic product is therapeutically equivalent to a reference listed drug. An "AB" rating denotes therapeutic equivalence and supports substitution in jurisdictions that permit it. Other codes (BX, AA, and form-specific variants) convey different equivalence conclusions. Check the Orange Book by product name, application number, or active ingredient, and verify the dosage form and strength specifically, because a single product may have different TE codes for different formulations.

For biologics, interchangeability determinations are tracked in the Purple Book rather than the Orange Book. Biological products listed as interchangeable may be substituted without prescriber intervention in states with applicable substitution laws, but confirm the state-specific rule before acting.

Drug vs device classification and combination products

FDA determines whether a product is a drug, device, biologic, or combination product based on statutory definitions and the product's primary mode of action. When the primary mode of action is chemical in the body, the product is typically regulated as a drug; when it is physical or mechanical, it is typically a device. Sponsors can obtain a formal center assignment by submitting a Request for Designation (RFD) to the Office of Combination Products (OCP) to resolve ambiguous cases before selecting a regulatory pathway.

Quick classification look-up checklist (authoritative links)

This checklist helps regulatory and compliance teams verify a product's status across the major U.S. classification systems. Work through only the steps relevant to your question.

1. Controlled substance status: Check DEA Drug Scheduling for the current schedule. Search the Federal Register for any rescheduling notices that may not yet be reflected on the main page.

2. Therapeutic and pharmacologic class (EPC): Search the product on DailyMed, open the current active label, and find the "Pharmacologic Class" field in the Highlights section for EPC, MoA, PE, and CS attributes.

3. Pregnancy and lactation risk: On DailyMed, navigate to Section 8, "Use in Specific Populations." Read the Pregnancy (8.1), Lactation (8.2), and Females and Males of Reproductive Potential (8.3) subsections rather than relying on legacy A–X letters.

4. Therapeutic equivalence (generic substitution): Search by product name or application number in the Orange Book. Verify the TE code for the specific dosage form and strength.

5. Recall status: Search FDA's Recalls, Market Withdrawals, & Safety Alerts database. Note the recall class (I, II, or III) and whether the recall is active or terminated.

6. OTC Monograph status: For OTC products, check FDA's OTC Monographs database to confirm whether the active ingredient and conditions of use fall under a final monograph order.

7. Biologics interchangeability: For biological products, check the Purple Book for licensure status, interchangeability designations, and exclusivity dates.

8. Drug vs. device or combination product: If the regulatory category is unclear, consult FDA's Office of Combination Products and consider submitting a Request for Designation.

Worked example: tracing one product across multiple systems

Consider a branded extended-release oral opioid analgesic under active NDA review. A regulatory analyst needs a complete multi-system classification record to support formulary policy, counseling language, and reporting obligations.

The analyst starts at DEA Drug Scheduling and confirms the active opioid ingredient is Schedule II — a finding that immediately drives controlled-substance storage, ordering procedures, and dispensing recordkeeping controls. The analyst then checks the Federal Register to confirm no rescheduling rulemaking is pending that could affect the product's handling requirements during the review period.

Next, the analyst opens the product's current label on DailyMed and locates the "Pharmacologic Class" line in the Highlights section. The entry reads "Opioid Agonist [MoA]" and "Full Opioid Agonist [PE]" — supporting accurate SPL indexing and formulary reporting. In Section 8 of the same label, the analyst reads the PLLR narrative on neonatal opioid withdrawal syndrome risk and documents the specific label language for policy updates, avoiding any reference to the legacy letter category.

The analyst then verifies a generic version in the Orange Book and finds an "AB" TE code for the specific extended-release formulation, indicating therapeutic equivalence and supporting substitution under applicable state law. A final search of FDA's recalls database confirms no active Class I or Class II recall for the product.

The result is a documented, four-system classification record with a clear source for each determination. Each system answered a different operational question; none could have substituted for another.

Which classification matters for your task?

Applying the wrong classification framework — or conflating systems without understanding which one legally governs a decision — is a common source of compliance errors. The mapping below ties common professional tasks to the correct framework and authoritative source.

Clinical counseling and substitution

For patient counseling on pregnancy and lactation risk, use PLLR narrative subsections in the approved label on DailyMed. For substitution decisions, use Orange Book TE codes to determine whether a generic is therapeutically equivalent and substitutable under state law. DEA schedules and EPC entries do not govern substitution decisions.

Compliance, storage, and security

For storage, dispensing controls, ordering procedures, and DEA registration requirements, use the DEA Drug Scheduling list. Recall classifications are relevant for market-withdrawal procedures and liability exposure; check FDA's recalls database separately as part of routine safety monitoring. EPC entries and TE codes do not determine physical security obligations.

Regulatory and labeling research

For regulatory submissions, labeling accuracy, and SPL attributes, use the EPC and related SPL fields on DailyMed and in the SPL XML. For biologics, consult the Purple Book for licensure, biosimilarity, and interchangeability information. For OTC pathway questions, consult FDA's OTC Monographs database to determine whether a product can be marketed without an NDA/BLA.

Regulatory teams managing submission workflows across multiple products and frameworks — tracking PDUFA dates, validating eCTD sequences, and monitoring biosimilar status — can use reference tools such as Assyro's PDUFA calendar and FDA Purple Book resource alongside the official FDA databases described above.

How to find a drug's FDA-established pharmacologic class (EPC) on a label

DailyMed is the National Library of Medicine's repository for FDA-approved labeling and displays EPC entries encoded in SPL. The steps below apply to any prescription drug or biologic with a current active label.

1. Go to DailyMed and search by brand name, generic name, or application number.

2. From the results, select the most recent active label for the specific product, dosage form, and strength.

3. Open the Highlights of Prescribing Information near the top and look for the "Pharmacologic Class" line or the "12 CLINICAL PHARMACOLOGY" subheading. The EPC appears there.

4. The EPC entry typically includes bracketed tags indicating whether the attribute reflects mechanism of action [MoA], physiologic effect [PE], or chemical structure [CS].

5. For programmatic or cross-product work, download the SPL XML from DailyMed to extract EPC attributes at scale.

How to check current DEA schedule and rescheduling notices

Use the DEA Drug Scheduling page for the current schedule list and consult the Federal Register for DEA proposed and final rules affecting scheduling. The process runs in sequence: FDA/HHS provides a scientific and medical evaluation, DEA initiates rulemaking, and DEA's final rule — once published in the Federal Register — defines the effective schedule.

For submission and portfolio tracking, teams should monitor both FDA review milestones and DEA rulemaking to anticipate scheduling impacts on controlled-substance candidates. A scheduling change that takes effect between IND filing and NDA approval can meaningfully alter post-approval commercialization plans, so tracking the rulemaking docket in parallel with the regulatory review timeline is prudent.

Interoperability caveats: EPC vs WHO ATC, and where RxNorm/UNII fit

The FDA EPC is a U.S. label-level regulatory designation supporting new-drug review and SPL indexing, not a universal drug taxonomy. The WHO Anatomical Therapeutic Chemical (ATC) system is a global hierarchical taxonomy used for drug utilization research and international epidemiology — its organizational logic differs substantially from EPC.

RxNorm provides normalized clinical drug names and identifiers used in electronic prescribing and clinical systems. UNII supplies unique ingredient identifiers for interoperability across datasets. Neither RxNorm nor UNII is a regulatory classification, but both support cross-system mapping and data exchange. Any mapping between EPC, ATC, RxNorm, and UNII should be validated case by case: the systems differ in granularity, update frequency, and the criteria used to assign categories.

Common confusions and mistakes to avoid

These errors appear regularly in practice when classification systems are conflated or applied beyond their intended scope.

• Treating DEA schedules as FDA classifications — scheduling is a DEA determination under the Controlled Substances Act; consult DEA's Drug Scheduling page.
• Confusing recall class with controlled-substance schedule — recall class describes market-removal risk severity; DEA schedules describe abuse potential and accepted medical use.
• Applying legacy A–X pregnancy categories to current labels — use PLLR narrative subsections on DailyMed; legacy letters remain only on labels not yet updated.
• Using Orange Book TE codes to infer clinical superiority — TE codes address pharmaceutical equivalence and bioequivalence for substitution, not comparative effectiveness.
• Assuming EPC maps directly to DEA schedules — pharmacologic class describes mechanism; scheduling reflects abuse potential and is decided by a separate authority through separate rulemaking.
• Applying FDA's new-drug-review classification beyond its intended scope — EPC was designed to guide new-drug review and labeling consistency, not to serve as a universal taxonomy for epidemiologic or formulary analysis.
• Overlooking the Purple Book for biologics interchangeability — use the Purple Book, not the Orange Book, for biosimilar interchangeability determinations.

Frequently asked questions

What does "FDA drug classification" actually refer to across U.S. drug frameworks?

It does not point to a single system. It may refer to DEA controlled substance schedules, FDA recall classes, FDA-established pharmacologic class (EPC) in labeling, PLLR pregnancy and lactation narratives, OTC Monograph/GRASE status, Orange Book TE codes, or the drug/device/combination determination. Each has a different authority, database, and operational purpose.

Is drug scheduling (Schedules I–V) handled by the FDA or the DEA, and how does FDA/HHS participate?

Scheduling is administered by DEA under the Controlled Substances Act. FDA/HHS provides scientific and medical evaluations and recommendations. DEA makes the final scheduling decision and publishes it in the Federal Register. See DEA Drug Scheduling.

How do I find a drug's FDA-established pharmacologic class (EPC) on DailyMed or the label?

Search DailyMed for the product, open the current active label, and look for the "Pharmacologic Class" line in the Highlights of Prescribing Information. The EPC appears with bracketed type tags (MoA, PE, CS).

Where can I check if a drug has an FDA recall and what Class I–III means?

Search FDA's Recalls, Market Withdrawals, & Safety Alerts database. Class I indicates a reasonable probability of serious adverse health consequences or death. Class II indicates possible temporary or reversible harm. Class III indicates use is not likely to cause adverse health consequences.

How do FDA recall classes differ from DEA schedules?

They are unrelated frameworks. Recall classes describe market-removal risk severity. DEA schedules describe abuse potential and accepted medical use. Consult FDA's recalls database for recalls and DEA's scheduling list for controlled-substance status.

How do I read current pregnancy and lactation risk information now that A–X categories were retired?

Find the approved label on DailyMed and navigate to Section 8, "Use in Specific Populations." PLLR-compliant labels present Pregnancy (8.1), Lactation (8.2), and Females and Males of Reproductive Potential (8.3) narrative subsections with risk summaries and clinical data.

What is the difference between therapeutic class, pharmacologic class, and mechanism of action on labels?

Therapeutic class is a broad functional grouping (e.g., analgesic). Pharmacologic class (EPC) is a label-specific regulatory designation with attributes including MoA, PE, and CS. Mechanism of action (MoA) is one attribute within EPC describing how the drug produces its effect at a molecular or receptor level.

How do Orange Book TE codes affect pharmacy substitution decisions?

An "AB" TE code indicates FDA has found a generic therapeutically equivalent to the reference listed drug and supports substitution under state law, absent a dispense-as-written instruction. TE codes apply to small-molecule drugs. Biologic interchangeability is addressed in the Purple Book.

What is the OTC Monograph (GRASE) pathway and how is it different from NDA/BLA approval?

The OTC Monograph sets conditions under which OTC active ingredients may be marketed without an NDA/BLA when they conform to a final monograph order. Products that do not conform must pursue an NDA/BLA. Consult FDA's OTC Monographs database for current orders.

When should I use FDA EPC vs WHO ATC, and what are the limits of mapping between them?

Use EPC for U.S. regulatory labeling, SPL indexing, and submission work. Use WHO ATC for international drug utilization and epidemiology. Any mapping requires validation because the systems differ in organizational logic and granularity.

How are borderline products classified when deciding between drug, device, or combination product rules?

FDA applies statutory definitions and assesses the primary mode of action. For ambiguous cases, sponsors can submit a Request for Designation to the Office of Combination Products to obtain a formal center assignment before committing to a regulatory pathway.

---

The clearest path through FDA drug classification is the same across all scenarios: identify which framework governs your specific decision, go to that framework's authoritative database, and document your source. For most regulatory and pharmacy operations tasks, that means picking from the checklist above — DEA for scheduling, DailyMed for EPC and PLLR, Orange Book for TE codes, Purple Book for biologics interchangeability, and FDA's recalls database for market-action status — rather than treating any single label or system as a universal answer. Teams managing active submission portfolios can pair those public lookups with workflow tools that track PDUFA dates, validate eCTD structure, and surface biosimilar status in one place; Assyro's free regulatory utilities and eCTD submission workspace are designed for exactly that context.